Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Contrast Enhancement in Magnetic Resonance Imaging
Conditions
Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers
Trial Timeline
Aug 26, 2020 → Apr 30, 2021
NCT ID
NCT06135181About Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo
Gadoquatrane (BAY1747846) 0.03 mmol Gd/kg + Gadoquatrane (BAY1747846) 0.1 mmol Gd/kg + Matching placebo is a phase 1 stage product being developed by Bayer for Contrast Enhancement in Magnetic Resonance Imaging. The current trial status is completed. This product is registered under clinical trial identifier NCT06135181. Target conditions include Contrast Enhancement in Magnetic Resonance Imaging, Healthy Volunteers.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06135181 | Phase 1 | Completed |
Competing Products
11 competing products in Contrast Enhancement in Magnetic Resonance Imaging
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| HRS-9231 + Gadobutrol | Jiangsu Hengrui Medicine | Phase 2 | 52 |
| Gadoquatrane (BAY1747846) | Bayer | Phase 3 | 74 |
| GBCAs | Bayer | Pre-clinical | 20 |
| BAY1747846 | Bayer | Phase 1 | 30 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoquatrane (BAY1747846) + Gadobutrol + Gadoterate meglumine + Gadoteridol | Bayer | Phase 3 | 74 |
| Gadoxetic acid disodium (Primovist, BAY86-4873) | Bayer | Approved | 82 |
| BAY1747846 + Matching placebo | Bayer | Phase 1 | 30 |
| Gadobutrol (Gadavist/Gadovist, BAY86-4875) | Bayer | Pre-clinical | 20 |
| Iopromide (Ultravist, BAY86-4877) | Bayer | Pre-clinical | 20 |
| Magnevist + Dotarem + Gadovist | Guerbet | Pre-clinical | 15 |